{
    "clinical_study": {
        "@rank": "82232", 
        "acronym": "RONDO", 
        "arm_group": {
            "arm_group_label": "Oxybutynin Extended-Release", 
            "arm_group_type": "Experimental", 
            "description": "Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects and tolerability (how well a\n      participant can stand a particular medicine or treatment) of flexible dose Oxybutynin\n      Extended-Release (OXY-ER, Lyrinel) including safety and quality of life assessment in\n      participants with neurogenic detrusor overactivity (NDO - the nerves mediating the detrusor\n      muscle do not work properly leading to frequent feeling of need to urinate during the day,\n      night, or both)."
        }, 
        "brief_title": "Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment. 'Number of participants analyzed for the baseline characteristic was intent-to-treat (ITT) population which included all randomly assigned participants who received at least 1 dose of study medication and fulfilled all eligibility criteria.'", 
                        "title": "Oxybutynin"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "15"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "20.2", 
                                            "@value": "52.7"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "3"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "12"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "28.1", 
                                            "@value": "57.7"
                                        }
                                    }
                                }
                            }, 
                            "description": "Maximal detrusor pressure represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. Detrusor pressure is the component of intravesical (in the bladder) pressure that is created by forces in the bladder wall (passive and active). It was estimated by subtracting abdominal pressure from intravesical pressure.", 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Maximal Detrusor Pressure", 
                            "units": "Centimeter of water"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Sponsor shall have first to present the data of Clinical Trial (CT) without approval from the Institution or PI. If the Institution and PI wish to publish data from CT, a copy of the same must be provided to Sponsor for review at least 60 days prior to submission. No paper with Confidential Information will be submitted with Sponsor\u2019s prior written consent. If requested in writing, Institution and PI will withhold publication for up to an additional 60 days to allow filing of patent application."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Maximal detrusor pressure represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. Detrusor pressure is the component of intravesical (in the bladder) pressure that is created by forces in the bladder wall (passive and active). It was estimated by subtracting abdominal pressure from intravesical pressure.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "15"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "29.7", 
                                                    "@value": "42.8"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Maximal detrusor pressure represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. Detrusor pressure is the component of intravesical (in the bladder) pressure that is created by forces in the bladder wall (passive and active). It was estimated by subtracting abdominal pressure from intravesical pressure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximal Detrusor Pressure", 
                                    "units": "Centimeter of water"
                                }
                            ]
                        }, 
                        "population": "The Intent-to treat (ITT) population included all randomly assigned participants who received at least 1 dose of study medication and fulfilled all eligibility criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 12", 
                        "title": "Maximal Detrusor Pressure", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "MCC represents the maximum volume of urine the bladder holds.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "15"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "55.2", 
                                                        "@value": "169.9"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "150.6", 
                                                        "@value": "268.8"
                                                    }
                                                }, 
                                                "sub_title": "Week 12"
                                            }
                                        ]
                                    }, 
                                    "description": "MCC represents the maximum volume of urine the bladder holds.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximal Cystometric Capacity (MCC)", 
                                    "units": "Milliliter (ml)"
                                }
                            ]
                        }, 
                        "population": "ITT population.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 12", 
                        "title": "Maximal Cystometric Capacity (MCC)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Detrusor leakpoint pressure is the level of pressure at which leakage of urine through the urethra occurs as the bladder fills without an increase in abdominal pressure. This was a measure of both strength of the urethral sphincters and compliance of the detrusor muscle.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Detrusor leakpoint pressure is the level of pressure at which leakage of urine through the urethra occurs as the bladder fills without an increase in abdominal pressure. This was a measure of both strength of the urethral sphincters and compliance of the detrusor muscle.", 
                                    "title": "Detrusor Leakpoint Pressure"
                                }
                            ]
                        }, 
                        "population": "Data for this outcome measure is not reported because the data was not collected and included in Case Report Form (CRF).", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 12", 
                        "title": "Detrusor Leakpoint Pressure", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Post-void residual urine volume is the amount of urine remaining in the bladder after void completion.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "7"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "79.8", 
                                                        "@value": "112.1"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 7)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "108.1", 
                                                        "@value": "184.5"
                                                    }
                                                }, 
                                                "sub_title": "Week 12 (n= 4)"
                                            }
                                        ]
                                    }, 
                                    "description": "Post-void residual urine volume is the amount of urine remaining in the bladder after void completion.", 
                                    "dispersion": "Standard Error", 
                                    "param": "Mean", 
                                    "title": "Post-Void Residual Urine Volume", 
                                    "units": "Milliliter (ml)"
                                }
                            ]
                        }, 
                        "population": "ITT population. Here \"N\" (number of participants analyzed) signifies participants who were evaluable for this measure and \"n\" signifies participants who were evaluable for this measure at a particular time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 12", 
                        "title": "Post-Void Residual Urine Volume", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Reflex volume is the infused volume that induces the first detrusor contraction.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Reflex volume is the infused volume that induces the first detrusor contraction.", 
                                    "title": "Reflex Volume"
                                }
                            ]
                        }, 
                        "population": "Data for this outcome measure is not reported because the data was not collected and included in Case Report Form (CRF).", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 12", 
                        "title": "Reflex Volume", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Urge incontinence episodes were reported. Urge urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency with sudden feeling to go to toilet.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.0", 
                                                        "@value": "8.8"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=14)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.4", 
                                                        "@value": "5.0"
                                                    }
                                                }, 
                                                "sub_title": "Week 4 (n=13)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.9", 
                                                        "@value": "4.9"
                                                    }
                                                }, 
                                                "sub_title": "Week 12 (n=13)"
                                            }
                                        ]
                                    }, 
                                    "description": "Urge incontinence episodes were reported. Urge urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency with sudden feeling to go to toilet.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Urge Incontinence Episodes", 
                                    "units": "Episodes"
                                }
                            ]
                        }, 
                        "population": "ITT population. Here \"n\" signifies participants who were evaluable for this measure at a particular time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 4 and Week 12", 
                        "title": "Urge Incontinence Episodes", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Episodes of total urinary incontinence were reported. Urinary incontinence is the complaint of any involuntary leakage of urine.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "10.7", 
                                                        "@value": "7.4"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=14)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.5", 
                                                        "@value": "4.2"
                                                    }
                                                }, 
                                                "sub_title": "Week 4 (n=13)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "12.0", 
                                                        "@value": "4.8"
                                                    }
                                                }, 
                                                "sub_title": "Week 12 (n=13)"
                                            }
                                        ]
                                    }, 
                                    "description": "Episodes of total urinary incontinence were reported. Urinary incontinence is the complaint of any involuntary leakage of urine.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Total Incontinence Episodes", 
                                    "units": "Episodes"
                                }
                            ]
                        }, 
                        "population": "ITT population. Here \"n\" signifies participants who were evaluable for this measure at a particular time point. This study is early terminated and there were some missing data for total incontinence which lead to decrease value of total incontinence.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 4 and Week 12", 
                        "title": "Total Incontinence Episodes", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Percentage of participants with no episodes of urge urinary incontinence was reported. Urge urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Percentage of participants with no episodes of urge urinary incontinence was reported. Urge urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency.", 
                                    "title": "Percentage of Participants With no Episodes of Urge-Urinary Incontinence"
                                }
                            ]
                        }, 
                        "population": "Data was not reported for this OM, as data was not analyzed because of change in the planned analysis of the study.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 4 and Week 12", 
                        "title": "Percentage of Participants With no Episodes of Urge-Urinary Incontinence", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "King Health Questionnaire assesses the physical and psycho-social aspects of the disease state. It is a self-administered questionnaire containing 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep or energy, and severity of urinary symptoms). All domains were assessed in a range: 0-100, where 0=best outcome/response and 100=worst outcome or response. Lower scores indicates better outcome or response.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                                "title": "Oxybutynin"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "21.6", 
                                                        "@value": "53.5"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: General Health Perceptions"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "30.5", 
                                                        "@value": "76.1"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Impact of Life"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "36.4", 
                                                        "@value": "66.7"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Role Limitations"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "22.4", 
                                                        "@value": "73.8"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Physical Limitations"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "29.0", 
                                                        "@value": "58.7"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Social Limitations"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "35.6", 
                                                        "@value": "66.7"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Personal Relationships"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "36.1", 
                                                        "@value": "57.1"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Emotions"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "24.9", 
                                                        "@value": "51.2"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Sleep or Energy"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "31.3", 
                                                        "@value": "44.0"
                                                    }
                                                }, 
                                                "sub_title": "Baseline: Incontinence Severity"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "16.2", 
                                                        "@value": "35.7"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: General Health Perceptions"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "29.8", 
                                                        "@value": "59.5"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Impact of Life"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "34.7", 
                                                        "@value": "63.1"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Role Limitations"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "27.7", 
                                                        "@value": "66.7"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Physical Limitations"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "32.5", 
                                                        "@value": "60.7"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Social Limitations"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "33.9", 
                                                        "@value": "30.9"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Personal Relationships"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "29.7", 
                                                        "@value": "41.3"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Emotions"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "33.1", 
                                                        "@value": "42.9"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Sleep or Energy"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "26.0", 
                                                        "@value": "33.9"
                                                    }
                                                }, 
                                                "sub_title": "Week 12: Incontinence Severity"
                                            }
                                        ]
                                    }, 
                                    "description": "King Health Questionnaire assesses the physical and psycho-social aspects of the disease state. It is a self-administered questionnaire containing 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep or energy, and severity of urinary symptoms). All domains were assessed in a range: 0-100, where 0=best outcome/response and 100=worst outcome or response. Lower scores indicates better outcome or response.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "King Health Questionnaire Score", 
                                    "units": "Units on a scale"
                                }
                            ]
                        }, 
                        "population": "ITT population. Here \"N\" signifies participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 12", 
                        "title": "King Health Questionnaire Score", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                        "title": "Oxybutynin"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lost to Follow-up"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "unspecified"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "17", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "15", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Treated"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "14", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "3", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "name_or_title": "Medical Affairs Director", 
                "organization": "Medical Affairs, Janssen-Cilag (Thailand)", 
                "phone": "662-792-7200 ext 5888"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Participants received an initial dose of extended release (ER) oxybutynin chloride 10 milligram (mg) orally once daily, with an increment of 5 mg in the dosage, at an approximate 14-days interval to a maximum of 30 mg per day, until continence was achieved for the last 2 days of interval. Dose was decreased by 5 mg if there were intolerable side effects. The participants then continued the maintenance dose to 12-week treatment.", 
                        "title": "Oxybutynin"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "12", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "11", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Dry mouth"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Constipation"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Vomitting"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Urinary tract infection"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Nerve compression"
                                    }
                                }, 
                                "title": "Injury, poisoning and procedural complications"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Back pain"
                                    }
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Pollakiuria"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Cystitis"
                                        }
                                    ]
                                }, 
                                "title": "Renal and urinary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Pharyngolaryngeal pain"
                                    }
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Rash"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "15"
                                            }, 
                                            "sub_title": "Pruritis"
                                        }
                                    ]
                                }, 
                                "title": "Skin and subcutaneous tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Orthostatic hypotension"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 7.1", 
                    "frequency_threshold": "0"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "15"
                                        }, 
                                        "sub_title": "Urinary tract infection"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 7.1"
                }, 
                "time_frame": "Baseline up to Week 12"
            }
        }, 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Detrusor Function, Overactive", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), single arm,\n      prospective (study following participants forward in time), multi-center study of\n      participants with NDO. The initial dose of Oxybutynin ER will be 10 milligram (mg) and will\n      be titrated to a maximum of 30 mg. Dosage will be adjusted in 5-mg increments at\n      approximately 14-day intervals until continence is achieved or the participant cannot\n      tolerate side effects. The duration of participation in the study will be 12 weeks. The\n      study will consist of 6 visits: baseline, Weeks 2, 4, 6, 8 and 12. Week 4 and Week 8 will be\n      telephone visits. Overall safety and efficacy of Oxybutinin ER will be assessed as well as\n      safety and efficacy during the titration and maintenance phases. The efficacy of treatment\n      will be assessed using urodynamic parameters (the force and flow of urine) and clinical\n      parameters (voiding diary and catheterization [use or insertion of a tubular device to drain\n      the bladder] schedules). The quality of life will also be monitored in the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of overactive bladder as a result of neurogenic condition, for example\n             following spinal cord injury, multiple sclerosis (slowly worsening disorder of the\n             central nervous system that causes symptoms such as weakness, incoordination,\n             numbness, problems talking and problems seeing), Parkinson's disease (a progressive\n             disorder of the central nervous system, seen usually in older persons, in which there\n             is slow movement [due to muscle weakness], trembling and sweating), or\n             cerebrovascular accidents (CVAs - stroke-sudden loss of blood supply to brain)\n\n          -  Women must not be pregnant and be of either non-childbearing potential or is using\n             adequate means of birth control\n\n          -  Overactive bladder symptoms and/or has urge incontinence episodes\n\n          -  Must have normal results on urine culture tests and on urinalysis\n\n          -  ECOG (Eastern Cooperative Oncology Group) performance status score of less than or\n             equal to 3\n\n        Exclusion Criteria:\n\n          -  Participants with 1 or more treatable or conditions, other than neurogenic bladder\n             dysfunction, that may cause urinary incontinence or urgency\n\n          -  Any medical or unstable condition that precludes their participation in the study or\n             may confound the outcome of the study (participants with or at risk for urinary\n             retention, gastric retention or uncontrolled narrow angle; heart failure or kidney\n             failure; diabetes mellitus; abnormal muscle weakness [myasthenia gravis]; paralysis\n             or inactivity in the intestines that prevents material moving through the gut\n             [intestinal atony or paralytic ileus]; severe inflammation of the bowel [ulcerative\n             colitis] sudden expansion of the large intestine seen in advanced ulcerative colitis\n             or Crohn's disease [toxic megacolon]; history of major lower urinary tract surgery\n             [transurethral resection will be excluded])\n\n          -  Hypersensitivity to the investigational drug or any of its ingredients (eg, lactose)\n\n          -  Pregnant or breast feeding female\n\n          -  Significant bacteriuria (presence of bacteria in the urine) or pyuria (presence of\n             white blood cells) in the urine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "firstreceived_results_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796548", 
            "org_study_id": "CR015205", 
            "secondary_id": "R016446OAB4011"
        }, 
        "intervention": {
            "arm_group_label": "Oxybutynin Extended-Release", 
            "description": "Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally", 
            "intervention_name": "Oxybutinin Extended-Release", 
            "intervention_type": "Drug", 
            "other_name": "Lyrinel"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxybutynin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Detrusor function, overactive", 
            "Urinary incontinence", 
            "Oxybutynin", 
            "Lyrinel"
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiangmai", 
                        "country": "Thailand"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phathumwan", 
                        "country": "Thailand"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Extended-Release Oxybutynin in the Treatment of Neurogenic Detrusor Overactivity (RONDO)", 
        "overall_official": {
            "affiliation": "Janssen-Cilag Ltd.,Thailand", 
            "last_name": "Janssen-Cilag Ltd.,Thailand Clinical trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Thailand: Food and Drug Administration, Ministry of Public Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Maximal detrusor pressure represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. Detrusor pressure is the component of intravesical (in the bladder) pressure that is created by forces in the bladder wall (passive and active). It was estimated by subtracting abdominal pressure from intravesical pressure.", 
            "measure": "Maximal Detrusor Pressure", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "MCC represents the maximum volume of urine the bladder holds.", 
                "measure": "Maximal Cystometric Capacity (MCC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "description": "Detrusor leakpoint pressure is the level of pressure at which leakage of urine through the urethra occurs as the bladder fills without an increase in abdominal pressure. This was a measure of both strength of the urethral sphincters and compliance of the detrusor muscle.", 
                "measure": "Detrusor Leakpoint Pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "description": "Post-void residual urine volume is the amount of urine remaining in the bladder after void completion.", 
                "measure": "Post-Void Residual Urine Volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "description": "Reflex volume is the infused volume that induces the first detrusor contraction.", 
                "measure": "Reflex Volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "description": "Urge incontinence episodes were reported. Urge urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency with sudden feeling to go to toilet.", 
                "measure": "Urge Incontinence Episodes", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and Week 12"
            }, 
            {
                "description": "Episodes of total urinary incontinence were reported. Urinary incontinence is the complaint of any involuntary leakage of urine.", 
                "measure": "Total Incontinence Episodes", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and Week 12"
            }, 
            {
                "description": "Percentage of participants with no episodes of urge urinary incontinence was reported. Urge urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency.", 
                "measure": "Percentage of Participants With no Episodes of Urge-Urinary Incontinence", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4 and Week 12"
            }, 
            {
                "description": "King Health Questionnaire assesses the physical and psycho-social aspects of the disease state. It is a self-administered questionnaire containing 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep or energy, and severity of urinary symptoms). All domains were assessed in a range: 0-100, where 0=best outcome/response and 100=worst outcome or response. Lower scores indicates better outcome or response.", 
                "measure": "King Health Questionnaire Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }
        ], 
        "source": "Janssen-Cilag Ltd.,Thailand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen-Cilag Ltd.,Thailand", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013", 
        "why_stopped": "Slow rate of participant's enrollment"
    }
}